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Abstract
The mineralocorticoid receptor (MR) is a ligand-activated transcription factor 
that transduces the effects of aldosterone and glucocorticoids in a tissue- and cell 
type-specific ways. Differential regulation of MR by post-translational modifica-
tions (PTMs) has been proposed to play a key role in modulating its function. In 
addition, modifications of other proteins that physically or functionally interact 
with MR add an additional layer of regulation to aldosterone or glucocorticoid sig-
naling. In this chapter, we will summarize the main post-translational modifications 
of MR described so far, discussing their possible implications in the physiologi-
cal and pathological roles of the receptor. We will also discuss post-translational 
modulation of other proteins impacting MR function such as heat shock protein 90 
or 11ß-hydroxysteroid dehydrogenase type 2.
Keywords: mineralocorticoid receptor, aldosterone, glucocorticoids,  
steroid receptors, protein modification, phosphorylation, Ubiquitylation, 
SUMOylation, acetylation
1. Introduction
The mineralocorticoid receptor (MR) is widely expressed and performs differ-
ent physiological and pathological roles depending not only on the activating ligand 
(aldosterone vs. glucocorticoids) but also on context [1–3]. This includes co-expression 
or not with 11ß-hydroxysteroid dehydrogenase (11ßHSD2) to control local levels of glu-
cocorticoids [4, 5], differential interaction with co-regulators [6] or the physiological 
mechanism behind the increased circulating levels of aldosterone [7], to name a few.
Multiple levels of regulation controlling MR activity have been described. 
Transcription of the Nr3c2 gene, coding for the receptor, is modulated by different 
stimuli and depends on two alternative promoters [1, 8]. Transcriptional control 
depending on epigenetic mechanisms has also been described [1]. MR transcripts 
undergo alternative splicing, although the physiological significance of these variants 
is uncertain [9]. Post-translational control includes regulation of MR mRNA stability 
by proteins such as Tis11b and HuR [10, 11] or siRNAs such as miR-124 and miR-135a 
[12–14]. Some MR polymorphisms have been shown to produce different transla-
tional efficiencies in vitro [15]. Once synthesized, MR activation depends on ligand 
availability, which in turn can be modulated by co-expression of 11ßHSD2, which 
creates a low glucocorticoid-microenvironment by metabolizing biologically active 
glucocorticoids to their 11-keto, biologically inactive derivatives [4, 5]. Activation 
also depends on the interaction of MR with co-chaperones, including Hsp70 and 
Hsp90 [16–18]. MR can also be activated in a ligand-independent manner by the 
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GTPase Rac1 [19] or by signaling through the angiotensin II receptor 1 [20]. Once 
activated, MR forms homodimers or, potentially, heterodimers with related steroid 
receptors including the glucocorticoid receptor (GR) [21, 22], translocates to the 
nucleus and interacts with DNA to modulate gene transcription with the help of co-
regulators. This provides the biological readout of hormone signaling and involves 
multiple and complex regulatory steps. In addition, MR activation can initiate rapid 
signaling events outside the nucleus that modulate cell response and are essential to 
facilitate transcriptional responses [23, 24].
Every step of MR activation and its impact on cell responses is subject to be 
modulated by post-translational modifications (PTMs) of the receptor itself or of 
other proteins physically or functionally interacting with it. PTMs of MR have been 
previously reviewed in detailed [25] (Figure 1). It has long been known that MR is 
a phosphoprotein [26, 27] and multiple MR residues have been described as poten-
tial phosphorylation targets [25]. Most of these amino acids are serine residues, 
although threonine phosphorylation has been detected using phospho-specific 
antibodies [28]. One study reported phosphorylation in threonine residues T731 
and S737 [29], although the functional impact of these modifications has not been 
studied. Of note, in a more recent study analyzing MR phosphopeptides by liquid 
chromatography with tandem mass spectrometry, Shibata et al. described 16 differ-
ent phosphorylated serine residues, but found no evidence of threonine or tyrosine 
phosphorylation [7]. In addition, other chemical modifications of MR have been 
described, including ubiquitylation [30–33], SUMOylation [32, 34, 35], acetyla-
tion [36] and oxidation [37]. In this chapter, we will update the main known PTMs 
directly or indirectly affecting MR and focus on their consequences on MR activity.
2. Post-translational modifications that alter MR stability
The abundance of naïve MR likely impacts the potency of receptor-mediated 
cell responses. There are numerous examples in the literature describing alteration 
of MR steady-state abundance in different physiological or pathological situations 
[2]. Changes in receptor abundance can arise from changes in its synthesis or in its 
degradation rates. In addition, an activation-induced MR degradation also seems 
to participate in controlling hormone responses [33]. Several MR PTMs have been 
shown to affect receptor half-life in the cell, both in the basal state and after hor-
monal stimulation.
Basal level of MR expression appears to be controlled by ubiquitylation 
(Figure 2). In the naïve state, MR is monoubiquitylated at an unknown lysine. This 
modification is stabilized by association to Tsg101 (tumor suppressor gene 101), 
increasing the half-life of the receptor [31]. This mechanism is shared by related 
1 All amino acid numbers in this chapter refer to the human MR sequence (UniProt P08235).
Figure 1. 
Schematic representation of MR protein domains and the location of post-translational modifications with 
demonstrated functional effects. NTD, NH2-terminal domain; DBD, DNA-binding domain; H, hinge domain; 
LBD, ligand-binding domain; AF, activation function. Phosphorylation sites (p) are shown with black letters; 
acetylation sites (ac) are shown in blue and SUMOylation sites (SUMO) are shown in red. The length of each 
domain and the position of each site are drawn to scale.
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steroid receptors such as the androgen, glucocorticoid and estrogen receptors 
[38–40]. In addition, it has been shown that poly-ubiquitylation occurs when Hsp90 
activity diminishes and the cytosolic heterocomplex recruits ubiquitin-ligase CHIP 
decreasing receptor expression level [41]. Taken together, these data suggest that 
equilibrium between mono- and poly-ubiquitylation contributes to regulating naïve 
MR abundance.
Ligand activation of MR induces receptor degradation through the protea-
some, acting as a brake to attenuate aldosterone responses [33]. Subsequent studies 
Figure 2. 
Schematic representation of well-characterized post-translational modifications affecting mineralocorticoid 
receptor ligand binding, stability, nuclear translocation or transcriptional activity. MR domain are colored as 
in Figure 1. L, ligand.
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demonstrated that MR is poly-ubiquitylated in response to hormonal stimulation 
[30–32, 42], a signal that triggers proteasomal-mediated degradation. Interestingly, 
it has been proposed that the equilibrium between mono- and poly-ubiquitylation of 
MR is regulated by phosphorylation. Remarkably, MR antagonists such as spirono-
lactone and finerenone totally block aldosterone-induced receptor phosphorylation, 
preventing the increased degradation rate associated to activation [43]. Aldosterone 
rapidly induces ERK1/2-mediated phosphorylation of MR at six different serine resi-
dues in the NTD (S196, S227, S238, S263, S287 and S361; Figure 1). The combined 
effect of these six phosphoserine residues is to promote the removal of mono- 
ubiquitylation from MR, triggering receptor destabilization [31]. Ubiquitin-specific 
protease 2-45 (USP2-45), an aldosterone-induced protein in the mouse distal neph-
ron [44], is responsible for the ligand-induced loss of MR mono-ubiquitylation, 
simultaneously destabilizing MR/Tsg101 interaction [30] (Figure 2). in agreement 
with the model described above data obtained with usp2 gene knockout mice showed 
increase expression of MR, although this change in abundance does not produce 
apparent alterations in sodium balance or blood pressure [45].
According to the model described above, phosphatases opposing MR ligand-
induced phosphorylation should contribute to stabilize the receptor. Interestingly, 
it has recently been described that protein phosphatase 1α (PP1α) indeed stabi-
lizes MR [42]. This study described PP1α as an MR cytosolic interaction partner. 
However, the effect of PP1α on MR appears to be indirect, mediated the dephos-
phorylation of ubiquitin ligase MDM2, which is inactivated, precluding MDM2-
mediated MR proteasomal degradation [42] (Figure 2).
Modification of additional residues in MR contributes to the receptor stability. 
For instance, Ruhs et al. recently described that MR phosphorylation at residue 
S459 (Figure 1), catalyzed by casein kinase 2 (CK2), not only facilitates MR-DNA 
interaction, increasing aldosterone-induced gene transcription (see below), but 
also promotes rapid degradation of MR [46]. The mechanism involved in enhanced 
MR degradation by S459 phosphorylation is unknown.
As mentioned above, it has been previously shown that MR stability is con-
trolled by Hps90 activity. When the co-chaperone is pharmacologically inhibited 
with tanespimycin, MR stability decreases through increase ubiquitylation medi-
ated by CHIP [41]. In contrast, a different inhibitor of Hsp90, geldanamycin, did 
not produce any alterations in MR levels [17]. To further explore the role on Hsp90 
on MR activation and stability, we tested the possible role of acetylation of Hsp90 
at residue K295 [47], a modification that impairs interaction with co-chaperones 
and client proteins [48]. Surprisingly, we could not find any evidence for Hsp90 
acetylation-induced alterations in MR stability [47], although this PTM did affect 
nuclear translocation dynamics (see below).
3.  Post-translational modifications that directly or indirectly control 
ligand binding to MR
Ligand binding capacity of MR is not an exclusively intrinsic property of the 
ligand-binding domain (LBD) of this receptor. It has long been known that MR 
association to the chaperone Hsp90 is essential for aldosterone binding [49, 50]. 
In addition, the full-length MR sequence is required to bind aldosterone with high 
affinity, suggesting that areas outside the LBD contribute to folding of the recep-
tor in a competent state [51]. The idea that PTMs may contribute to regulate MR 
ligand binding came from the observation that phosphatase treatment of cytosolic 
extracts greatly diminish aldosterone binding to MR [27]. This suggested that basal 
phosphorylation in serine/threonine residues is essential for the competency of the 
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receptor to bind ligands. However, these experiments did not allow distinguishing 
whether the phosphorylation takes place in the receptor itself or in other proteins 
of the cytosolic heterocomplex containing the naïve receptor. More recently, direct 
evidence implicating phosphorylation on ligand binding to MR has emerged. 
Phosphorylation of MR at residue S843 has been shown to diminish the affinity 
of the receptor for aldosterone and corticosterone [7]. This process is mediated 
by protein kinase ULK1 [52]. Interestingly, phosphomimetic mutants cannot be 
activated by aldosterone or cortisol even when the concentration of the hormones 
is one to two orders of magnitude higher than the calculated Kd, indicating that 
phosphorylation affects not only ligand binding but also ligand-induced recep-
tor activation [53]. Importantly, phosphorylation of MR at residue S843 acts as a 
dominant-negative modification, inhibiting wild type receptors upon dimerization, 
which greatly amplifies the impact of this event on total MR activity [53].
Ligand binding to MR is also affected by oxidation. It has long been known that 
MR is a highly unstable protein and this has been ascribed to sulfhydryl oxidation, 
which prevents aldosterone binding [37, 54]. In particular, cysteine 849 and 942 
appear to be responsible for this effect, since site-directed mutagenesis at these posi-
tions eliminate steroid binding to the receptor [55]. This phenomenon appears to be 
relevant in vivo, since inhibition of glutathione synthetase in mice abrogated aldoste-
rone binding to kidney MR [56]. Since oxidative stress decreases aldosterone binding 
and activation and aldosterone binding decreases with age, it has been suggested that 
oxidation of MR could be an important mediator of aging in the kidney [57].
In classic aldosterone tissues like the kidney or the distal colon and in certain 
neurons, glucocorticoid accessibility to MR is crucially controlled by co-expression 
of 11ßHSD2, which metabolizes glucocorticoids to produce biologically inactive, 
11-keto derivatives [4]. Therefore, transcriptional or post-transcriptional modu-
lations of this enzyme potentially have a large impact on MR activity. We have 
recently described that 11ßHSD2 is modified by SUMOylation at residue K266 
[58] (Figure 2). While the effect of SUMOylation on enzymatic activity is mild, its 
impact on MR activation process is puzzling. In spite of being enzymatically active, 
non-SUMOylatable mutant 11ßHSD2-K266R was unable to prevent MR nuclear 
translocation when cells were treated with cortisol, unlike the wild type enzyme 
[58]. The same was detected when 11ßHSD2 SUMOylation is reversed by co-
expression of sentrin-specific protease 1 (SENP1), a protease that catalyzes SUMO 
deconjugation. However, MR translocated to the nucleus under these conditions 
does not increase transcriptional response to cortisol and shows diminished recruit-
ment of co-activators [58]. Therefore, 11ßHSD2 SUMOylation drastically alters the 
ability of this enzyme to regulate MR subcellular localization, although the molecu-
lar mechanisms involved in this effect remain to be elucidated.
4. Post-translational modifications that alter MR nuclear translocation
Long-term, genomic actions of MR depend on its nuclear localization and inter-
action with chromatin. While some steroid receptor (ER and PR) are constitutively 
nuclear, naïve MR is considered to be mainly cytosolic, where it forms part of a het-
erocomplex with chaperones and other proteins, translocating to the nucleus after 
ligand binding. In fact, it is most common to find MR evenly distributed between 
nucleus and cytosol, with a clear nuclear shift when exposed to ligands. This mode 
of action fits well with data obtained in some models of cultured cell lines, such 
as COS-7 cells or HEK cells [17, 43, 47, 59] and native tissues [60–62]. In certain 
tissues and cell types, MR can be found in the nucleus even in the absence of ligand 
[18, 60, 61]. Therefore, it appears that nuclear translocation plays an important role 
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in MR regulation, although the physiological relevance of this step may strongly 
vary between different tissues or cell types.
Nuclear translocation has been studied with much more detail in the case of 
other steroid receptors, including GR, which shares significant sequence homology 
with MR. In the case of GR, two independent nuclear translocation pathways have 
been proposed, one that depends on Hsp90 and the attachment of the ligand-bound 
heterocomplex to microtubules and one where monomers or dimers of GR translocate 
independently of this machinery [63]. In the case of MR, there is strong evidence indi-
cating that nuclear translocation occurs in an Hsp90-dependent way, with dissociation 
between the chaperone and the receptor occurring in the nucleus [16, 17]. Inhibition 
of Hsp90 abrogates hormone binding to MR and nuclear translocation of the receptor, 
although cells with low levels of Hsp90 expression such as cardiomyocytes present 
constitutively nuclear MR that can be activated by aldosterone or cortisol [18]. This 
result suggested that fine-tuning of Hsp90 activity could play a role in controlling MR 
subcellular localization. Therefore, we decided to explore the role of Hsp90 acetyla-
tion at residue K295 in MR nuclear translocation [47]. This modification, regulated by 
histone deacetylase 6 (HDAC6), inhibits Hsp90 and has been shown to decrease GR 
and AR activity [48]. In the case of MR, increased acetylation of Hsp90 does not affect 
ligand binding or transcriptional activity, but alters subcellular dynamics, accelerating 
MR nuclear import. Given the differential effects of Hsp90 K295 acetylation on MR 
and GR, it has been proposed that this modification may balance corticosteroid signal-
ing between both receptors when co-expressed in the same cell [47].
Nuclear translocation of MR critically depends on nuclear localization signals 
(NLS) present in the sequence of the receptor. Three independent NLS has been 
identified in MR: NL0, 1 and 2 [64]. Among these three, NL0 has been implicated in 
nuclear localization of the naïve receptor. NL0 was mapped to amino acids 550–602 
of human MR. In this area, a cluster of five serine residues and one threonine between 
amino acids 590 and 602 is important for NL0 activity, since its deletion significantly 
decreases naïve MR nuclear localization, although it does not abrogate ligand-induced 
translocation [64]. Interestingly, phosphomimicking mutation S601D (Figures 1 
and 2) eliminated NL0 activity, resulting in a fully cytosolic MR localization in the 
absence of ligand. Conversely, non-phosphorylatable mutant S601A resulted in a 
significant nuclear shift of naïve MR [64]. Therefore, phosphorylation/dephosphory-
lation balance at S601 may be an important mechanism for controlling MR subcellular 
distribution in the absence of ligand. The effect of this equilibrium on the physiology 
of the receptor remains to be studied. Both in vitro and in vivo experiments indicate 
that a protein phosphatase from the PP1/PP2A subgroup regulates ligand-induced 
MR trafficking into the nucleus [65], although it is unclear whether this results from 
dephosphorylation of MR or other associated proteins such as Hsp90.
Aldosterone-induced nuclear translocation is potentiated by Rac1-mediated 
phosphorylation of p21-activated kinase 1 (PAK1) (Figure 2). This signaling path-
way is relevant in the development of chronic kidney disease [19] and in cardiac 
remodeling and inflammation induced by blood pressure variability in the context 
of hypertension [66]. It remains to be determined whether PAK1 directly phosphor-
ylates MR and whether it promotes its activity in addition to receptor translocation, 
as it has been described with estrogen receptors [67].
5.  Post-translational modifications controlling MR activation and 
modulating gene transcription
In addition to the mechanisms discussed above modulating MR ligand binding, 
stability and subcellular localization, additional PTMs regulate the ability of MR to 
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modulate gene transcription, potentially altering the efficacy of the receptor with-
out altering its affinity for agonists. This possibility was suggested after studying a 
human polymorphism introducing the mutation Y73C, which increases MR trans-
activation in response to aldosterone by twofold, without changing the EC50 [68]. 
Residue Y73 is placed in AF1a and therefore could modulate interaction with tran-
scriptional co-activators. However, there are no further reports demonstrating that 
this potential phosphorylation site is actually modified in the protein. Le Moellic 
et al. proposed a possible role for phosphorylation in controlling MR transcriptional 
activity [28]. This study found that protein kinase C α (PKCα) mediates rapid MR 
phosphorylation at serine/threonine residues after stimulation with aldosterone, 
which presumably acts through a membrane receptor [28]. Blocking PKCα during 
this early, non-genomic phase precludes the development of the genomic phase. 
However, whether this effect is directly due to lack of activation of MR or, alterna-
tively modulation of other aspects of the receptor such as aldosterone binding or 
nuclear translocation was not studied.
More direct evidence of phosphorylation involvement in controlling MR activ-
ity came from studying the effect of cyclin-dependent kinase 5 (CKD5) on the 
receptor. CKD5 has been proposed to phosphorylate two residues in the NTD of 
MR (S1282, T159 and S250; Figure 1), producing a very powerful decrease in MR 
transcriptional activity without affecting nuclear translocation [69] (Figure 2). 
The phosphorylation is mediated by direct interaction of the CKD5/p35 or CKD5/
p25 complexes with MR LBD in an aldosterone-dependent way [69]. T159 and S250 
phosphorylation could be confirmed by mass spectrometry, while phosphorylation 
at residue S128 was inferred from mutagenesis studies. Mutation of all three resi-
dues to alanine was necessary to abolish CKD5-dependent MR inhibition [69].
As indicated above, CK2-dependent MR S459 phosphorylation (Figure 1) facili-
tates MR-DNA interaction, at least in an in vitro assay, and increases aldosterone- 
induced gene transcription [46]. This effect is partially mediated by the NTD of 
the receptor, where the phosphorylation site is located, possibly by promoting 
MR-CK2 interaction in a process that needs Hsp90 activity. Interestingly, phospho-
mimetic mutation S459D not only increased aldosterone-induced responses but also 
resulted in ligand-independent transcriptional activation (Figure 2). Modeling a 
pro-inflammatory environment by treating cultured cells with a cytokine cocktail 
increased CK2 expression, resulting in enhanced MR modification, leading to 
increase receptor activity and activating NFκB signaling and thus enhancing the 
expression of proinflammatory genes [46]. This could provide a mechanism to 
help explain the deleterious effects of MR activity in the context of inflamma-
tion, as demonstrated in endothelial cells [71]. The mechanism underlying altered 
MR activity by CK2 phosphorylation remains unclear. The authors speculated 
that S459 phosphorylation could induce a conformational change that promotes 
MR-DNA interaction or alternatively enhance MR association with transcriptional 
co- activators [46]. The latter possibility is plausible, since residue S459 lies in AF-1b 
within the NTD, a region involved in the interaction between MR and transcrip-
tional co-regulators in a ligand-independent manner [72].
MR acetylation at residue K677 (Figures 1 and 2) inhibits its transcriptional 
activity by preventing MR and RNA polymerase II recruitment to target gene 
promoters. Surprisingly, K677 acetylation did not affect MR nuclear translocation 
[36], even though this residue is located in NL1. This study and subsequent work by 
2 Human MR has serine residues at positions 127 and 129, but not at position 128. The authors refer to this 
residue as residing “in the perfect motif of CDK5 phosphorylation site” [69], which is [S/T]PX[K/R/H] 
[70]. Residue S129 fits this description and therefore it is likely that the authors refer to it instead of residue 
128, which is a methionine.
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the same group identified CREB-binding protein (CRE)/p300 as the acetylase and 
HDAC3 as the deacetylase responsible for modifying K677 [36, 73] (Figure 2). The 
molecular basis for the lack of MR binding to target promoters when acetylated at 
residue K677, which is away from the DBD, is unknown.
Addition of small ubiquitin modifier (SUMO) proteins to five different lysine 
residues in MR (Figure 1), all located within a SUMOylation consensus site, has 
been proposed to alter its transcriptional activity and co-regulator recruitment 
[32, 34, 35]. The first description of MR SUMOylation followed the identification of 
protein inhibitor of activated STAT-1 (PIAS1), a SUMO E3 ligase, as an MR interact-
ing partner using a yeast two-hybrid assay using the NTD of the receptor as bait 
[34]. The functional consequences of PIAS1-mediated SUMOylation are complex. 
Co-expression of PIAS1 with MR led to repression of receptor-mediated gene trans-
activation in two different model promoters, the mouse mammary tumor virus pro-
moter (MMTV) and an artificial glucocorticoid response element (GRE) promoter 
[34]. However, introducing non-SUMOylatable mutations in the receptor did not 
produce the expected opposite effects in MMTV, which was unaffected. In contrast, 
the same mutations increased MR activity on the GRE promoter. Taken together, 
these results suggest that the effect of PIAS1 on MR is promoter-dependent and 
may occur through different mechanisms including direct receptor SUMOylation 
and perhaps SUMOylation of transcriptional co-regulators. In addition, PIAS1 may 
exert additional modulatory activities independent of its SUMO ligase activity. This 
possibility is suggested by the observation that a PIAS1 SUMO ligase-dead mutant 
W363A is still able to inhibit androgen receptor transcriptional activity [74]. The 
complexity of SUMOylation-dependent regulation of MR activity is illustrated by 
the fact that the E2 SUMO ligase responsible for its SUMOylation, Ubc9, is able 
to recruit steroid receptor coactivator-1 (SRC-1) to form a complex with MR and 
activate its transcriptional activity independently of addition of SUMO residues to 
the receptor [35]. Therefore, the two enzymes playing a role on MR SUMOylation, 
PIAS1 and Ubc9 (Figure 2), can have opposing effects on the receptor transcrip-
tional activity in a promoter-dependent way, suggesting that many of these actions 
occur through modification/recruitment of co-regulators.
6. Summary and perspectives
Many PTM sites have been identified in MR, but only some of them have been 
experimentally linked to alterations in MR function (Figures 1 and 2). These 
include modulation of MR ligand-binding ability, stability, nuclear translocation 
and gene transactivation. In addition, MR-associated proteins such as Hsp90, 
11ßHSD2 or ubiquitin ligases such as MDM2 are also modulated by PTMs, adding 
further regulatory possibilities for fine-tuning MR activity. This complex picture 
is not unexpected, given the near ubiquitous distribution of MR and the diverse 
functional roles played by this receptor in response to two different types of ligands, 
mineralocorticoids and glucocorticoids. Therefore, it will not be surprising to find 
new PTMs directly or indirectly implicated in the regulation of MR activity. In 
addition, ligand-dependency of MR PTMs needs to be addressed with more detail. 
In principle, changes in MR conformation induced by different ligands could affect 
accessibility to modification sites. Differential PTM in response to different agonists 
or antagonists could potentially underlie divergent effects of MR-mediated signal-
ing events. Generally, detailed characterization of the functional effects of PTMs 
is feasible in cultured cells. However, the main challenge remains to elucidate the 
physiological or pathological importance of these modifications in whole organisms 
and the clinical relevance that they may have in humans.
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Due to the nature of steroid receptors, including MR, they are inherently drug-
gable targets. Excess signaling through MR has now been firmly established as an 
important factor in hypertension, heart failure and ocular diseases, with compelling 
evidence indicating further implication in brain, vascular, renal, metabolic and skin 
diseases [2]. Therefore, there is renewed interest in developing MR modulators with 
tissue-specific characteristics that may reduce or avoid undesirable side effects. 
Given the high degree of homology between LBDs of different steroid receptors, a 
significant effort to develop nonsteroidal inhibitors is underway [75]. In addition, it 
is possible that allosteric inhibitors or small molecules able to modulate MR protein-
protein interactions may provide new strategies to manipulate the system. PTMs 
may have an important effect on drug binding and future drug development, both 
for competitive and allosteric modulators. In fact, recent in silico approaches have 
explored this possibility, exploiting the increasing availability of high-throughput 
PTM screenings and high-resolution protein three-dimensional structures [76]. 
It can be expected that improved PTM screening, combined with structural and 
computational methods will provide new testable hypotheses regarding the regula-
tion of steroid receptors and possible new ways of pharmacological modulation of 
their activities.
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